Allergan plc (NYSE: AGN) recently received a number of ratings updates from brokerages and research firms:

  • 9/21/2016 – Allergan plc was downgraded by analysts at Cantor Fitzgerald from a “buy” rating to a “hold” rating.
  • 9/20/2016 – Allergan plc was given a new $294.00 price target on by analysts at Bank of America Corp.. They now have a “buy” rating on the stock.
  • 9/14/2016 – Allergan plc had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $305.00 price target on the stock.
  • 9/12/2016 – Allergan plc had its “buy” rating reaffirmed by analysts at Goldman Sachs Group Inc..
  • 8/30/2016 – Allergan plc had its “neutral” rating reaffirmed by analysts at Piper Jaffray Cos.. They now have a $227.00 price target on the stock.
  • 8/22/2016 – Allergan plc was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $288.87 price target on the stock.
  • 8/19/2016 – Allergan plc was upgraded by analysts at Mizuho from a “neutral” rating to a “buy” rating. They now have a $318.00 price target on the stock, up previously from $248.00.
  • 8/15/2016 – Allergan plc was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $283.05 price target on the stock.
  • 8/10/2016 – Allergan plc had its “outperform” rating reaffirmed by analysts at RBC Capital Markets. They now have a $300.00 price target on the stock, down previously from $307.00.
  • 8/9/2016 – Allergan plc had its price target lowered by analysts at Royal Bank Of Canada from $307.00 to $300.00. They now have an “outperform” rating on the stock.
  • 8/9/2016 – Allergan plc had its price target lowered by analysts at Deutsche Bank AG from $282.00 to $278.00. They now have a “buy” rating on the stock.
  • 8/9/2016 – Allergan plc was given a new $227.00 price target on by analysts at Piper Jaffray Cos.. They now have a “hold” rating on the stock.
  • 8/8/2016 – Allergan plc was given a new $294.00 price target on by analysts at Leerink Swann. They now have a “buy” rating on the stock.
  • 8/8/2016 – Allergan plc was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $283.05 price target on the stock.
  • 8/5/2016 – Allergan plc had its price target raised by analysts at Mizuho from $232.00 to $246.00. They now have a “neutral” rating on the stock.
  • 8/5/2016 – Allergan plc was given a new $325.00 price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 8/3/2016 – Allergan plc was given a new $322.00 price target on by analysts at Credit Suisse Group AG. They now have a “hold” rating on the stock.
  • 8/2/2016 – Allergan plc was downgraded by analysts at Vetr from a “strong-buy” rating to a “buy” rating. They now have a $276.34 price target on the stock.
  • 8/1/2016 – Allergan plc was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $285.60 price target on the stock.
  • 7/27/2016 – Allergan plc had its price target raised by analysts at Leerink Swann from $272.00 to $294.00. They now have an “outperform” rating on the stock.
  • 7/26/2016 – Allergan plc was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Allergan has been pretty active on the acquisition front. With the Allergan, Inc. acquisition, Allergan, which was previously known for its strong presence in the generics market, finds itself in the company of the top 10 pharma companies across the world based on sales. Allergan has been actively working on expanding its presence in the branded market. The upcoming sale of its generics business to Teva will allow Allergan to focus on its branded segment. Moreover, the company will use the proceeds to buy back shares, pay down debt and pursue additional deals. Biosimilars also represent significant opportunity. While we remain optimistic about the company’s growth prospects, we note that integration risks remain. Moreover, the company is facing generics for Namenda IR as well as patent challenges for some of the other products in its branded portfolio.”
  • 7/25/2016 – Allergan plc is now covered by analysts at Credit Suisse Group AG. They set an “outperform” rating and a $327.00 price target on the stock.
  • 7/25/2016 – Allergan plc was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $285.60 price target on the stock.

Allergan plc (NYSE:AGN) traded up 1.66% during midday trading on Thursday, hitting $242.36. The company had a trading volume of 1,058,843 shares. The firm has a market capitalization of $95.96 billion, a P/E ratio of 23.08 and a beta of 0.73. Allergan plc has a 1-year low of $195.50 and a 1-year high of $322.68. The company has a 50 day moving average price of $245.19 and a 200 day moving average price of $243.01.

Allergan plc (NYSE:AGN) last issued its earnings results on Monday, August 8th. The company reported $3.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.34 by $0.01. The company earned $3.68 billion during the quarter, compared to analyst estimates of $4.10 billion. Allergan plc had a return on equity of 7.67% and a net margin of 28.06%. The firm’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the business posted $4.41 EPS. Equities research analysts forecast that Allergan plc will post $14.01 earnings per share for the current fiscal year.

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Ratings for Allergan plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan plc and related companies with MarketBeat.com's FREE daily email newsletter.